Skip to content

Released Aug 9, 2018, before the open

10-Q filed Aug 9, 2018, 40 days after period end · 0001144204-18-043286

Q2 2018 · 10-Q
Revenue$2.01M−68.4% vs Q2 2017−55.9% vs Q1 2018
Net Income-$8.46MN/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$0.06N/M vs Q2 2017N/M vs Q1 2018
Gross Profit-$177,000N/M
Operating Income-$6,744,000N/M
Operating Cash Flowderived-$7,964,000N/M
Free Cash Flowderived-$8,109,000N/M
Margins · derived
Gross margin-8.8%−22.0 pt vs Q2 2017
Operating margin-336.2%−166.2 pt vs Q2 2017
Net margin-421.8%−428.9 pt vs Q2 2017

What the release said

The release

Same quarter

MetricQ2 2018Q2 2017Q2 2016Q2 2015
Revenue$2.01M$6.36M$1.77M$1.34M
Net Income-$8.46M$450.00K-$10.85M-$5.07M
EPS Diluted-$0.06-$0.06-$0.11-$0.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR